otelixizumab (TAB-H52)

Anti-Human CD3E Therapeutic Antibody TAB-H52 1mg Please Inquiry


  • Product Overview
  • Recombinant Humanized (from rat) antibody to Human CD3E. Otelixizumab, also known as TRX4, is a monoclonal antibody, which is being developed for the treatment of type 1 diabetes and other autoimmune diseases.
  • Type
  • IgG1 - lambda
  • Species Reactivity
  • Human
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, WB and most other immunological methods.
  • CAS
  • 881191-44-2
  • Specificity
  • CD3E (CD3 epsilon) [Homo sapiens]
  • Protein Construction
  • humanized gamma1 heavy chain 299N>A [humanized VH (Homo sapiens FR/Rattus sp. CDR) (119 residues [8.8.12]) -Homo sapiens IGHG1*01, 180N>A (CH2 84.4)] (222-216")-disulfide withchimeric lambda light chain 111G>R [Rattus sp. V-LAMBDA (110 residues [8.3.9]) – Homo sapiens IGLC2*01, 1G>R (1.5)] ; (228-228"​: 231-231"​) –bisdisulfide dimer
  • Purity
  • Purity >95% by SDS-PAGE.


  • Antigen Description
  • CD3e molecule, epsilon also known as CD3E is a polypeptide which in humans is encoded by the CD3E gene which resides on chromosome 11.
  • Function
  • SH3 domain binding; T cell receptor binding; protein heterodimerization activity; protein kinase binding; receptor activity; receptor signaling complex scaffold activity; receptor signaling protein activity; transmembrane signaling receptor activity;
  • Synonyms
  • CD3E; CD3e molecule, epsilon (CD3-TCR complex); CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; T-cell antigen receptor complex, epsilon subunit of T3; T3E; TCRE; FLJ18683;

Related Products

Online Inquiry

Verification code
Click image to refresh the verification code.


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us